Home / Dacomitinib / United States
US ATC L01EB07 · updated 2 Nov 2026
Dacomitinib shortage in United States
Is there a Dacomitinib shortage in United States?
Yes. As of 2 Nov 2026, 3 Dacomitinib products are reported short in United States, the first since 8 Jun 2026. No return date has been given. Main reason: not stated.
Not reported short in any other country we track. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Vizimpro, Tablet, 15 mg (NDC 0069-0197-30) discontinuation | Pfizer Inc. | 8 Jun 2026 | not given | Not stated |
| US | Vizimpro, Tablet, 30 mg (NDC 0069-1198-30) discontinuation | Pfizer Inc. | 8 Jun 2026 | not given | Not stated |
| US | Vizimpro, Tablet, 45 mg (NDC 0069-2299-30) discontinuation | Pfizer Inc. | 8 Jun 2026 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).